Skip to main content
Top
Published in: Current Gastroenterology Reports 1/2011

01-02-2011

Management of Refractory Ascites and Hepatorenal Syndrome

Authors: Amy N. Sussman, Thomas D. Boyer

Published in: Current Gastroenterology Reports | Issue 1/2011

Login to get access

Abstract

One of the most common manifestations of the development of portal hypertension in the patient with cirrhosis is the appearance of ascites. Once ascites develops, the prognosis worsens and the patient becomes susceptible to complications such as bacterial peritonitis, hepatic hydrothorax, hyponatremia, and complications of diuretic therapy. As the liver disease progresses, the ascites becomes more difficult to treat and many patients develop renal failure. Most patients can be managed by diuretics which, when used correctly, will control the ascites. Spontaneous bacterial peritonitis can be treated effectively, but portends a worse prognosis. Once the ascites becomes refractory to diuretics, liver transplantation is the best option, although use of transjugular intrahepatic portosystemic shunts will control the ascites in many patients. Lastly, the development of hepatorenal syndrome indicates the patient’s liver disease is advanced, and transplantation again is the best option. However, use of vasoconstrictors may improve renal function in some patients, helping in their management while they await a liver transplant.
Literature
1.
go back to reference Planas R, Montoliu S, Balleste B, et al.: Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385–94.CrossRefPubMed Planas R, Montoliu S, Balleste B, et al.: Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385–94.CrossRefPubMed
2.
go back to reference Salerno F, Camma C, Enea M, et al.: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825–34.CrossRefPubMed Salerno F, Camma C, Enea M, et al.: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825–34.CrossRefPubMed
3.
go back to reference Gines P, Cardenas A: The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43–58.CrossRefPubMed Gines P, Cardenas A: The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43–58.CrossRefPubMed
4.
go back to reference Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.CrossRefPubMed Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.CrossRefPubMed
5.
go back to reference Bernard B, Grange J-D, Khac EN, et al.: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. A meta-analysis. Hepatology 1999;29:1655–61.CrossRefPubMed Bernard B, Grange J-D, Khac EN, et al.: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. A meta-analysis. Hepatology 1999;29:1655–61.CrossRefPubMed
6.
go back to reference Fernandez J, Navasa M, Planas R, et al.: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818–24.CrossRefPubMed Fernandez J, Navasa M, Planas R, et al.: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818–24.CrossRefPubMed
7.
go back to reference Angeli P, Wong F, Watson H, et al.: Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535–42.CrossRefPubMed Angeli P, Wong F, Watson H, et al.: Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535–42.CrossRefPubMed
8.
go back to reference Boyer TD: Tolvaptan and hyponatremia. Hepatology 2010;51:699–702.PubMed Boyer TD: Tolvaptan and hyponatremia. Hepatology 2010;51:699–702.PubMed
9.
go back to reference Schrier RW, Gross P, Gheorghiade M, et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099–2112.CrossRefPubMed Schrier RW, Gross P, Gheorghiade M, et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099–2112.CrossRefPubMed
10.
go back to reference • Kim WR, Biggins SW, Kremers WK, et al.: Hyponatremia and mortality among patients waiting for liver transplantation. N Engl J Med 2008;359:1018–26. This work defined the influences of hyponatremia on survival in patients with advanced liver disease. Hyponatremia is an independent risk factor of death and may be added to the MELD score for determining which patients should receive an organ for liver transplantation. CrossRefPubMed • Kim WR, Biggins SW, Kremers WK, et al.: Hyponatremia and mortality among patients waiting for liver transplantation. N Engl J Med 2008;359:1018–26. This work defined the influences of hyponatremia on survival in patients with advanced liver disease. Hyponatremia is an independent risk factor of death and may be added to the MELD score for determining which patients should receive an organ for liver transplantation. CrossRefPubMed
12.
go back to reference Boyer TD, Haskel Z: AASLD Practice Guidelines: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386–400.CrossRefPubMed Boyer TD, Haskel Z: AASLD Practice Guidelines: The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386–400.CrossRefPubMed
13.
go back to reference Arroyo V, Gines P, Guevara M, Rodes J: Renal dysfunction in cirrhosis: pathophysiology, clinical features and therapy. In Hepatology: A textbook of liver disease, Ed. 5, Zakim D and Boyer TD eds, WB Saunders, 2006, p. 417–452. Arroyo V, Gines P, Guevara M, Rodes J: Renal dysfunction in cirrhosis: pathophysiology, clinical features and therapy. In Hepatology: A textbook of liver disease, Ed. 5, Zakim D and Boyer TD eds, WB Saunders, 2006, p. 417–452.
14.
go back to reference Tito L, Gines P, Arroyo V, et al.: Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146–51.PubMed Tito L, Gines P, Arroyo V, et al.: Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146–51.PubMed
15.
go back to reference Angermayr B, Cejna M, Koenig F, et al.: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents. Hepatology 2003;38:1043–50.PubMed Angermayr B, Cejna M, Koenig F, et al.: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents. Hepatology 2003;38:1043–50.PubMed
16.
go back to reference Nair S, Verma S, Thuluvath PJ: Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;1179–85. Nair S, Verma S, Thuluvath PJ: Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;1179–85.
17.
go back to reference Weismuller TJ, Prokein J, Becker T, et al.: Prediction of survival after liver transplantation by pre-transplant parameters. Scan J Gastroenterol 2008;43:736–746.CrossRef Weismuller TJ, Prokein J, Becker T, et al.: Prediction of survival after liver transplantation by pre-transplant parameters. Scan J Gastroenterol 2008;43:736–746.CrossRef
18.
go back to reference Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilaton hypothesis: a proposal for the initation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.CrossRefPubMed Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilaton hypothesis: a proposal for the initation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.CrossRefPubMed
19.
go back to reference • Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009;361;13: 1279–1290. This excellent review discusses the pathogenesis of renal failure in patients with cirrhosis. Also, current treatments are reviewed and guidelines provided to the clinician on evaluation and management of the patient with cirrhosis and renal failure. CrossRefPubMed • Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009;361;13: 1279–1290. This excellent review discusses the pathogenesis of renal failure in patients with cirrhosis. Also, current treatments are reviewed and guidelines provided to the clinician on evaluation and management of the patient with cirrhosis and renal failure. CrossRefPubMed
20.
go back to reference Iwakiri Y: The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;Suppl 3:S288–S294.CrossRef Iwakiri Y: The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;Suppl 3:S288–S294.CrossRef
21.
go back to reference Martin, PY, Ginès P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533–541.CrossRefPubMed Martin, PY, Ginès P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533–541.CrossRefPubMed
22.
go back to reference Arroyo V, Ginès P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164–176.CrossRefPubMed Arroyo V, Ginès P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164–176.CrossRefPubMed
23.
go back to reference Wiest R, Das S, Cadelina G, et al.: Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin Invest 1999;104:1223–1233.CrossRefPubMed Wiest R, Das S, Cadelina G, et al.: Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin Invest 1999;104:1223–1233.CrossRefPubMed
24.
25.
go back to reference Albillos A, de la Hera A, González M, et al.: Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208–217.CrossRefPubMed Albillos A, de la Hera A, González M, et al.: Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208–217.CrossRefPubMed
26.
go back to reference Fraces R, Zapater P, Gonzalez M, et al.: Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008;47:978–985.CrossRef Fraces R, Zapater P, Gonzalez M, et al.: Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008;47:978–985.CrossRef
27.
go back to reference Bataller R, Ginès P, Guevara M, Arroyo V: Hepatorenal syndrome. Semin Liver Dis 1997;17:233–247.CrossRefPubMed Bataller R, Ginès P, Guevara M, Arroyo V: Hepatorenal syndrome. Semin Liver Dis 1997;17:233–247.CrossRefPubMed
28.
go back to reference Wadeo HM, Mai ML, Absan N, Gonwa TA: Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:1066.CrossRef Wadeo HM, Mai ML, Absan N, Gonwa TA: Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006;1:1066.CrossRef
29.
go back to reference Salerno F, Gerbes A, Ginès P, et al.: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310–1318.PubMed Salerno F, Gerbes A, Ginès P, et al.: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310–1318.PubMed
30.
go back to reference MacAulay J, Thompson K, Kibert BA, et al.: Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction; are the equations for estimating renal function better? Can J Gastroenterol 2006;20:521–526.PubMed MacAulay J, Thompson K, Kibert BA, et al.: Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction; are the equations for estimating renal function better? Can J Gastroenterol 2006;20:521–526.PubMed
31.
go back to reference Moore KP, Wong F, Ginès P, et al.: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Heptatology 2003;38:258–266.CrossRef Moore KP, Wong F, Ginès P, et al.: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Heptatology 2003;38:258–266.CrossRef
32.
go back to reference Salerno F, Gerbes A, Gines P, et al.: Diagnosis, prevention, and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the International Ascites Club. Gut 2007;56:1310–1318.PubMed Salerno F, Gerbes A, Gines P, et al.: Diagnosis, prevention, and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the International Ascites Club. Gut 2007;56:1310–1318.PubMed
33.
go back to reference • Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–2077. The causes of renal failure in patients admitted with cirrhosis are defined. Most patients with cirrhosis and renal failure do not have hepatorenal syndrome, but instead have types of renal failure that are reversible. The clinician needs to be aware of all causes of renal failure in this patient population so that appropriate therapy can be given. CrossRefPubMed • Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–2077. The causes of renal failure in patients admitted with cirrhosis are defined. Most patients with cirrhosis and renal failure do not have hepatorenal syndrome, but instead have types of renal failure that are reversible. The clinician needs to be aware of all causes of renal failure in this patient population so that appropriate therapy can be given. CrossRefPubMed
34.
go back to reference Angeli P, Merkel C: Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48:Suppl 1:S93–S103.CrossRefPubMed Angeli P, Merkel C: Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48:Suppl 1:S93–S103.CrossRefPubMed
36.
37.
go back to reference Gluud LL, Kjaer MS, Christensen E: Terlipressin for hepatorenal syndrome. Cochrane Database Sys Rev 2006;4:CD005162. Gluud LL, Kjaer MS, Christensen E: Terlipressin for hepatorenal syndrome. Cochrane Database Sys Rev 2006;4:CD005162.
38.
go back to reference Martin-Llahi M, Pepin MN, Guevara M, et al.: Terlipressin and albumin vs. Albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352–1359.CrossRefPubMed Martin-Llahi M, Pepin MN, Guevara M, et al.: Terlipressin and albumin vs. Albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352–1359.CrossRefPubMed
39.
go back to reference • Sanyal AK, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double blind, placebo-controlled study of terlipressin for type I hepatorenal syndrome. Gastroenterology 2008, 134:1360–1368. This is the largest placebo-controlled trial of a vasopressor in the treatment of hepatorenal syndrome type 1. Terlipressin reversed renal failure in more patients as compared to those receiving placebo. The results of this and other trials establish that the hyperdynamic circulation and resulting renal underperfusion are the basis for the development of the hepatorenal syndrome. CrossRefPubMed • Sanyal AK, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double blind, placebo-controlled study of terlipressin for type I hepatorenal syndrome. Gastroenterology 2008, 134:1360–1368. This is the largest placebo-controlled trial of a vasopressor in the treatment of hepatorenal syndrome type 1. Terlipressin reversed renal failure in more patients as compared to those receiving placebo. The results of this and other trials establish that the hyperdynamic circulation and resulting renal underperfusion are the basis for the development of the hepatorenal syndrome. CrossRefPubMed
40.
go back to reference Duvoux C, Zanditenas D, Hézode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome.: a pilot study. Hepatology 2002;36:374–380.CrossRefPubMed Duvoux C, Zanditenas D, Hézode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome.: a pilot study. Hepatology 2002;36:374–380.CrossRefPubMed
41.
go back to reference Angeli P, Volpin R, Gerunda G, et al.: Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999:29:1690–1697.CrossRefPubMed Angeli P, Volpin R, Gerunda G, et al.: Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999:29:1690–1697.CrossRefPubMed
42.
go back to reference Esrailian E, Pantangco ER, Kyulo NL, et al.: Octreotide/midodrine therapy significnatly improves renal function and 30-day survival in patients with type I hepatorenal syndrome. Dig Dis Sci 2007;52:742–748.CrossRefPubMed Esrailian E, Pantangco ER, Kyulo NL, et al.: Octreotide/midodrine therapy significnatly improves renal function and 30-day survival in patients with type I hepatorenal syndrome. Dig Dis Sci 2007;52:742–748.CrossRefPubMed
43.
go back to reference Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.: Octreotide in hepatorenal syndrome: a randomized, double-bline, placebo-controlled, crossover study. Hepatology 2003;1:238–243.CrossRef Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.: Octreotide in hepatorenal syndrome: a randomized, double-bline, placebo-controlled, crossover study. Hepatology 2003;1:238–243.CrossRef
44.
go back to reference Alessandria C, Ozdogan O, Guevara M, et al.: MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282–1289.CrossRefPubMed Alessandria C, Ozdogan O, Guevara M, et al.: MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282–1289.CrossRefPubMed
45.
go back to reference Gonwa TA, Klintmalm GB, Levy M, et al.: Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361–365.PubMed Gonwa TA, Klintmalm GB, Levy M, et al.: Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361–365.PubMed
46.
go back to reference Restuccia T, Ortega R, Guevara M, et al.: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140–146.CrossRefPubMed Restuccia T, Ortega R, Guevara M, et al.: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140–146.CrossRefPubMed
47.
go back to reference Wong LP, Blackley MP, Andreoni KA, et al.: Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005;1:362–370.CrossRef Wong LP, Blackley MP, Andreoni KA, et al.: Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005;1:362–370.CrossRef
48.
go back to reference Wong F, Sniderman K, Liu P, Blendis L: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 3:899–907.CrossRef Wong F, Sniderman K, Liu P, Blendis L: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 3:899–907.CrossRef
49.
go back to reference Guevara M, Ginès P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416–422.CrossRefPubMed Guevara M, Ginès P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416–422.CrossRefPubMed
50.
go back to reference Brensing KA, Textor J, Perz J, et al.: Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288–295.CrossRefPubMed Brensing KA, Textor J, Perz J, et al.: Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288–295.CrossRefPubMed
51.
go back to reference Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type I hepatorenal syndrome. Hepatology 2004;40:55–64.CrossRefPubMed Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type I hepatorenal syndrome. Hepatology 2004;40:55–64.CrossRefPubMed
52.
go back to reference Rasaratnam B, Kaye D, Jennings G, et al.: The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. Ann Intern Med 2003;139:186–193.PubMed Rasaratnam B, Kaye D, Jennings G, et al.: The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. Ann Intern Med 2003;139:186–193.PubMed
Metadata
Title
Management of Refractory Ascites and Hepatorenal Syndrome
Authors
Amy N. Sussman
Thomas D. Boyer
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 1/2011
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0156-6

Other articles of this Issue 1/2011

Current Gastroenterology Reports 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.